Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes

References

• AhmadFKHeZKingGLMolecular targets of diabetic cardiovascular complicationsCurr Drug Targets200564879416026267
   PubMed Web of Science ®Google Scholar
• AndersonJWKendallCWJenkinsDJImportance of weight management in type 2 diabetes: review with meta-analysis of clinical studiesJ Am Coll Nutr200322331914559925
   PubMed Web of Science ®Google Scholar
• AronoffSLBerkowitzKSchreinerBGlucose metabolism and regulation: beyond insulin and glucagonDiabetes Spectrum20041718390
   Google Scholar
• AstrupAHealthy lifestyles in Europe: prevention of obesity and type 2 diabetes by diet and physical activityPublic Health Nutr2001449951511683545
   PubMedGoogle Scholar
• Barrett-ConnorEFerraraAIsolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: The Rancho Bernardo StudyDiabetes Care199821123699702426
   PubMed Web of Science ®Google Scholar
• BeckmanJACreagerMALibbyPDiabetes and atherosclerosis: epidemiology, pathophysiology, and managementJAMA200228725708012020339
   PubMed Web of Science ®Google Scholar
• BlondeLHanJMacSExenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetesDiabetes200554A118477-P
   Google Scholar
• BonoraEMuggeoMPostprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidenceDiabetologia20014421071411793012
   PubMed Web of Science ®Google Scholar
• BoseAKMocanuMMCarrRDGlucagon-like peptide1 can directly protect the heart against ischemia/reperfusion injuryDiabetes2005541465115616022
   PubMed Web of Science ®Google Scholar
• BrownleeMThe pathobiology of diabetic complications. A unifying mechanismDiabetes20055416152515919781
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care20042726283515504997
   PubMed Web of Science ®Google Scholar
• BYETTA®Prescribing information [online]2005San Diego, CA, USAAmylin Pharmaceuticals Inc Accessed on 1 July 2005. URL: http://www.byetta.com/
   Google Scholar
• CaliffRHolmanRon behalf of the NAVIGATOR Trial Group 2003People at increased risk of cardiovascular disease screenedfor the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance [Abstract and poster]52nd annual scientific session of the American College of CardiologyMarch 30 – April 2Chicago116951
   Google Scholar
• CaumoALuziLFirst-phase insulin secretion: does it exist in real life? Considerations on shape and functionAm J Physiol Endocrinol Metab2004287E371E38515308473
   PubMed Web of Science ®Google Scholar
• CerielloAMechanisms of tissue damage in the postprandial stateInt J Clin Pract Suppl2001Sep12371211594300
   PubMedGoogle Scholar
• CerielloAPostprandial hyperglycemia and diabetes complications: is it time to treat?Diabetes2005541715616004
   PubMed Web of Science ®Google Scholar
• CoutinhoMGersteinHCWangYThe relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 yearsDiabetes Care1999222334010333939
   PubMed Web of Science ®Google Scholar
• CreutzfeldtWThe incretin concept todayDiabetologia197916758532119
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAToft-NielsenMBoth subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2–terminus in type II diabetic patients and in healthy subjectsDiabetes1995441126317657039
   PubMed Web of Science ®Google Scholar
• DeaconCFTherapeutic strategies based on glucagon-like peptide 1Diabetes2004532181915331525
   PubMed Web of Science ®Google Scholar
• [DECODE] DECODE study groupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteriaArch Inter Med2001161397405
   PubMedGoogle Scholar
• DeFronzoRAPharmacological therapy for type 2 diabetes mellitusAnn Intern Med199913128130310454950
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care200528109210015855572
   PubMed Web of Science ®Google Scholar
• DegnKBBrockBJuhlCBEffect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemiaDiabetes200453239740315331551
   PubMed Web of Science ®Google Scholar
• DruckerDJEnhancing incretin action for the treatment of type 2 diabetesDiabetes Care20032629294014514604
   PubMed Web of Science ®Google Scholar
• EganJMClocquetARElahiDThe insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetesJ Clin Endocrinol Metab20028728290
   Web of Science ®Google Scholar
• EngJKleinmanWASinghLIsolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venomJ Biol Chem1992267740251313797
   PubMed Web of Science ®Google Scholar
• ErdmannEDiabetes and cardiovascular risk markersCurr Med Res Opin200521S21815811196
   PubMed Web of Science ®Google Scholar
• FehseFTrautmannMHolstJJExenatide augments first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab2005905991716144950
   PubMed Web of Science ®Google Scholar
• FinemanMSBicsakTAShenLZEffect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesDiabetes Care2003262370712882864
   PubMed Web of Science ®Google Scholar
• GokeRFehmannHCLinnTExendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cellsJ Biol Chem19932681965058396143
   PubMed Web of Science ®Google Scholar
• GoldsteinGBeneficial health effects of modest weight lossIn J of Obes199216397415
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRonnemaaTMortality from coronary heart disease in sugjects with type 2 diabetes and in nondiaetic subjects with and without prior myocardial infarctionN Engl J Med1998339229349673301
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med20051435596916230722
   PubMed Web of Science ®Google Scholar
• HirschIBIntensifying insulin therapy in patients with type 2 diabetes mellitusAm J Med200511821S6S15850550
   PubMed Web of Science ®Google Scholar
• HolstJJTherapy of type 2 diabetes mellitus based on the action of glucagon-like peptide-1Diabetes/Metab Res Rev20021843041
   PubMed Web of Science ®Google Scholar
• HomePContributions of basal and post-prandial hyperglycemia to micro- and macrovascular complication in people with type 2 diabetesCurr Med Res Opin2005219899816004665
   PubMed Web of Science ®Google Scholar
• KahnSEThe importance of the beta cell in the pathogenesis of type 2 diabetes mellitusAm J Med20001082S8S10764844
   PubMedGoogle Scholar
• KannelWBMcGeeDLDiabetes and cardiovascular disease: the Framingham StudyJAMA197924120358430798
   PubMed Web of Science ®Google Scholar
• KaufmanFRType 2 diabetes in children and young adults: A “new epidemic”Clin Diabetes20022021718
   Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care20052810839115855571
   PubMed Web of Science ®Google Scholar
• KendallDMKimDPoonTImprovements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wkDiabetes200554A4–516–OR
   Web of Science ®Google Scholar
• KhawKTWarehamNLubenRGlycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Perspective Investigation of Cancer and Nutrition (EPIC-Norfolk)BMJ20013221611141128
   PubMedGoogle Scholar
• KleinRHyperglycemia and microvascular and macrovascular disease in diabetesDiabetes Care199918258687729308
   PubMedGoogle Scholar
• KoltermanOGBuseJBFinemanMSSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab2003883082912843147
   PubMed Web of Science ®Google Scholar
• KoltermanOGKimDDShenLPharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitusAm J Health Sys Pharmacy20056217381
   PubMed Web of Science ®Google Scholar
• KreymannBWilliamsGGhateiMAGlucagon-like peptide-1 7-36: a physiological incretin in manLancet19872130042890903
   PubMed Web of Science ®Google Scholar
• MaggioCAPi-SunyerFXThe prevention and treatment of obesity. Application to type 2 diabetesDiabetes Care1997201744669353619
   PubMed Web of Science ®Google Scholar
• MeigsJBNathanDMD'AgostinoRBFasting and postchallenge glycemia and cardiovascular disease risk. The Framingham Offspring StudyDiabetes Care2002101845912351489
   PubMedGoogle Scholar
• MokdadAHFordESBowmanBADiabetes trends in the US: 1990–1998Diabetes Care20002212788310977060
   PubMedGoogle Scholar
• MonnierLColetteCRabasa-LhoretRMorning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetesDiabetes Care2002257374111919134
   PubMed Web of Science ®Google Scholar
• MorrishNJWangSLStevensLKMortality and causes of death in the WHO multinational study of vascular disease in diabetesDiabetologia200144S142111587045
   PubMed Web of Science ®Google Scholar
• [NCEP] National Cholesterol Education ProgramThird report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final reportCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• NauckMStockmannFEbertRReduced incretin effect in type 2 (non-insulin-dependent) diabetesDiabetologia19862946523514343
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCNormalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia19933674148405741
   PubMed Web of Science ®Google Scholar
• NielsenLLYoungAAParkesDPharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetesRegul Pept2004117778814700743
   PubMed Web of Science ®Google Scholar
• NikolaidisLAMankadSSokosGGEffects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusionCirculation2004109962514981009
   PubMed Web of Science ®Google Scholar
• NystromTGutniakMKZhangQEffects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary heart diseaseAm J Physiol Endocrinol Metab2004a287E12091515353407
   PubMed Web of Science ®Google Scholar
• NystromTGononATSjoholmAGlucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanismRegul Pept2004b125173715582729
   PubMedGoogle Scholar
• ParkesDGPittnerRJodkaCInsulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitroMetabolism200150583911319721
   PubMed Web of Science ®Google Scholar
• PerleyMKipnisDMPlasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjectsJ Clin Invest1967461954626074000
   PubMed Web of Science ®Google Scholar
• PoonTNelsonPShenLExenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a doseranging studyDiabetes Technol Ther200574677715929678
   PubMedGoogle Scholar
• PurnellJQWeyerCWeight effects of current and experimental drugs for diabetes mellitusTreat Endocrin200323347
   PubMedGoogle Scholar
• ReavenGMBanting Lecture: Role of insulin resistance in human diseaseDiabetes19883715956073056758
   PubMed Web of Science ®Google Scholar
• SingletonJRSmithAGRussellJWMicrovascular complications of impaired glucose toleranceDiabetes20035228677314633845
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycemia with mascrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ20003214051210938048
   PubMed Web of Science ®Google Scholar
• ThumAHupe-SodmannKGokeREndoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4Exp Clin Endocrinol Diabetes20021101131812012270
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab20018637172311502801
   PubMed Web of Science ®Google Scholar
• TominagaMEguchiHManakaHImpaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata StudyDiabetes Care199922920410372242
   PubMed Web of Science ®Google Scholar
• [UKPDS] United Kingdom Prospective Diabetes Study GroupIntensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• VidalJUpdated review on the benefits of weight lossInt J Obes200226S258
   PubMed Web of Science ®Google Scholar
• WilliamsonDFThompsonTJThunMIntentional weight loss and mortality among overweight individuals with diabetesDiabetes Care200023149950411023143
   PubMed Web of Science ®Google Scholar
• YoungAAGedulinBRBhavsarSGlucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)Diabetes19994810263410331407
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLEffect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyLancet20023598243011897280
   PubMed Web of Science ®Google Scholar